XRAY in the 13F filings
Dentsply Sirona Inc · CUSIP 24906P109
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 18 Oct 2023
- Managers listing it
- 15
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 10 listed it in both
- Shares listed
- 48,978,136
- combined, among listed positions
- Reported value
- $1.7bn
- combined, at the quarter end
Managers listing XRAY in Q3 2023
15 of 15 holders
Largest increases and reductions, by shares
Increases
- ARK Investment Management LLCnew position · 128,242 shares now+128,242
- Bridgewater Associates LPexisting position · 366,438 shares now+24,796
- Brevan Howard Capital Management LPnew position · 8,600 shares now+8,600
- GAMCO Investors Incexisting position · 60,294 shares now+850
Reductions
- T. Rowe Price Associates Incexisting position · 6,079,233 shares now-938,921
- Balyasny Asset Management LLCexisting position · 967,834 shares now-678,804
- Artisan Partners LPexisting position · 12,935,314 shares now-539,039
- Janus Henderson Group Ltdexisting position · 7,425,339 shares now-298,395
- Arrowstreet Capital LPexisting position · 1,206,643 shares now-212,872
New positions and exits
New (2)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2016 | 17 | $3.1bn | n.a. | n.a. |
| Q2 2016 | 18 | $3.0bn | n.a. | n.a. |
| Q3 2016 | 15 | $2.8bn | n.a. | n.a. |
| Q4 2016 | 14 | $2.7bn | n.a. | n.a. |
| Q1 2017 | 19 | $2.7bn | n.a. | n.a. |
| Q2 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q3 2017 | 13 | $2.6bn | n.a. | n.a. |
| Q4 2017 | 12 | $2.6bn | n.a. | n.a. |
| Q1 2018 | 17 | $1.4bn | n.a. | n.a. |
| Q2 2018 | 12 | $933m | n.a. | n.a. |
| Q3 2018 | 18 | $1.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $1.6bn | n.a. | n.a. |
| Q1 2019 | 13 | $1.8bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.1bn | n.a. | n.a. |
| Q3 2019 | 16 | $1.9bn | n.a. | n.a. |
| Q4 2019 | 16 | $2.0bn | n.a. | n.a. |
| Q1 2020 | 16 | $1.5bn | n.a. | n.a. |
| Q2 2020 | 16 | $2.1bn | n.a. | n.a. |
| Q3 2020 | 14 | $2.3bn | n.a. | n.a. |
| Q4 2020 | 11 | $2.7bn | n.a. | n.a. |
| Q1 2021 | 16 | $3.7bn | n.a. | n.a. |
| Q2 2021 | 23 | $3.8bn | n.a. | n.a. |
| Q3 2021 | 18 | $3.3bn | n.a. | n.a. |
| Q4 2021 | 13 | $2.8bn | n.a. | n.a. |
| Q1 2022 | 16 | $2.8bn | n.a. | n.a. |
| Q2 2022 | 18 | $2.0bn | n.a. | n.a. |
| Q3 2022 | 17 | $1.5bn | n.a. | n.a. |
| Q4 2022 | 14 | $1.6bn | n.a. | n.a. |
| Q1 2023 | 11 | $2.2bn | n.a. | n.a. |
| Q2 2023 | 10 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 15 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 13 | $1.7bn | 9 | 7 |
| Q1 2024 | 12 | $1.1bn | 8 | 5 |
| Q2 2024 | 9 | $781m | 7 | 3 |
| Q3 2024 | 8 | $941m | 6 | 2 |
| Q4 2024 | 9 | $648m | 8 | 2 |
| Q1 2025 | 9 | $586m | 8 | 2 |
| Q2 2025 | 8 | $639m | 3 | 6 |
| Q3 2025 | 6 | $369m | 4 | 2 |
| Q4 2025 | 5 | $199m | 23 | 9 |
| Q1 2026 | 7 | $273m | 17 | 17 |
| Q2 2026 | 5 | $61m | 10 | 19 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
XRAY and LLY →XRAY and JNJ →XRAY and VRTX →Choose a stock to compare with XRAY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own XRAY, latest filings →Back to the 13F Explorer →